/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

GH RESEARCH PLC Share Price Today: Live Updates & Key Insights

GH RESEARCH PLC share price today is $15.83, up 2.58%. The stock opened at $14.93 against the previous close of $15.13, with an intraday high of $15.735 and low of $14.93.

GH RESEARCH PLC Share Price Chart

style
pb-0

GH RESEARCH PLC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

GH RESEARCH PLC Share Price Performance

$15.83 0.0258(2.58%) GHRS at 13 Mar 2026 01:18 PM Biotechnology
Lowest Today 14.93
Highest Today 15.735
Today’s Open 14.93
Prev. Close 15.13
52 Week High 19.51
52 Week Low 7.98
Day’s Range: Low 14.93 High 15.735
52-Week Range: Low 7.98 High 19.51
1 day return -
1 Week return -3.32
1 month return +5.18
3 month return +23.95
6 month return +16.9
1 year return +40.56
3 year return +76.83
5 year return -21.24
10 year return -

GH RESEARCH PLC Institutional Holdings

Bvf Inc 14.23

Lynx1 Capital Management, LP 13.87

RA Capital Management, LLC 12.38

RTW INVESTMENTS, LLC 9.57

FMR Inc 8.28

Fidelity Growth Compy Commingled Pl S 4.16

Cormorant Asset Management, LLC 3.09

venBio Select Advisor LLC 2.90

Fidelity Growth Company Fund 2.51

Deep Track Capital, LP 2.02

Millennium Management LLC 1.39

RTW Biotech Opportunities Ord 1.30

Jefferies Financial Group Inc 1.14

Verition Fund Managegment, LLC 1.09

5AM Venture Management, LLC 0.92

Fidelity Growth Company K6 0.85

UBS Group AG 0.82

Fidelity Series Growth Company 0.61

iShares Biotechnology ETF 0.54

HighVista Strategies LLC 0.39

Alyeska Investment Group, L.P. 0.33

Marshall Wace Asset Management Ltd 0.27

CenterBook Partners LP 0.27

BOOTHBAY FUND MANAGEMENT, LLC 0.18

Citadel Advisors Llc 0.15

Fidelity Select Biotechnology 0.15

AdvisorShares Psychedelics ETF 0.13

Point72 Asset Management, L.P. 0.12

iShares MSCI Ireland ETF 0.09

iShares Nasdaq US Biotech ETF USD Acc 0.08

Fidelity Nasdaq Composite Index 0.06

A4Investments SICAV SIF ACCI IlanaA2EURH 0.05

Arrow Long/Short Alt Fd F 0.05

Arrow Opportunities Alternative Series F 0.05

Virtus LifeSci Biotech Clinical Trls ETF 0.03

Exemplar Performance Series F 0.02

State Street® SPDR® S&P® Intl Sm Cp ETF 0.02

TEQ- Disruptive Tech In I-III 0.01

Northern Small Cap Core I 0.01

Invesco Nasdaq Biotechnology ETF 0.01

GH RESEARCH PLC Market Status

Strong Buy: 5

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

GH RESEARCH PLC Fundamentals

Market Cap 938.50 M

PB Ratio 3.2207

PE Ratio 0.0

Enterprise Value 650.58 M

Total Assets 288.23 M

Volume 432137

GH RESEARCH PLC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-315000 -0.3M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-35587000 -35.6M, FY22:-7135000 -7.1M, FY21:-9211000 -9.2M, FY20:-446000 -0.4M, FY19:-310000 -0.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-89000 -0.1M, Q2/2025:-82000 -0.1M, Q1/2025:-76000 -0.1M, Q3/2024:null 0.0M, Q2/2024:-78000 -0.1M

Quarterly Net worth Q3/2025:-14020000 -14.0M, Q2/2025:-9289000 -9.3M, Q1/2025:-10812000 -10.8M, Q3/2024:-12114000 -12.1M, Q2/2024:-10379000 -10.4M

About GH RESEARCH PLC & investment objective

Company Information GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Organisation Biotechnology

Employees 50

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow